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Abstract
Background: Recent studies on the association between miR-146a rs2910164 polymorphism and risk of gastrointestinal (GI)
cancers showed inconclusive results. Accordingly, we conducted a comprehensive literature search and a meta-analysis to
clarify the association.
Methodology/Principal Findings: Data were collected from the following electronic databases: Pubmed, Excerpta Medica
Database (Embase), and Chinese Biomedical Literature Database (CBM), with the last report up to February 24, 2012. The
odds ratio (OR) and its 95% confidence interval (95%CI) were used to assess the strength of association. Ultimately, a total of
12 studies (4,817 cases and 5,389 controls) were found to be eligible for meta-analysis. We summarized the data on the
association between miR-146a rs2910164 polymorphism and risk of GI cancers in the overall population, and performed
subgroup analyses by ethnicity, cancer types, and quality of studies. In the overall analysis, there was no evidence of
association between miR-146a rs2910164 polymorphism and the risk of GI cancers (G versus C: OR=1.07, 95%CI 0.9821.16,
P=0.14; GG+GC versus CC: OR=1.14, 95%CI 1.0021.31, P=0.05; GG versus GC+CC: OR=1.06, 95%CI 0.9121.23, P=0.47; GG
versus CC: OR=1.17, 95%CI 0.9521.44, P=0.13; GC versus CC: OR=1.14, 95%CI 1.0021.31, P=0.05). Similar results were
found in the subgroup analyses by ethnicity, cancer types, and quality of studies.
Conclusions/Significance: This meta-analysis demonstrates that miR-146a rs2910164 polymorphism is not associated with
GI cancers susceptibility. More well-designed studies based on larger sample sizes and homogeneous cancer patients are
needed.
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Introduction
MicroRNAs (miRNAs) are small, non-coding, endogenous
RNAs that represent a significant mechanism of post transcrip-
tional gene regulation [1]. It has been demonstrated that miRNAs
have a crucial function in affecting processes as varied as cellular
differentiation, proliferation, metabolism, apoptosis, and tumori-
genesis [2]. Several miRNA expression analyses in human
epithelial malignancies have shown that distinct tumor specific
miRNA signatures can distinguish different cancer types and
classify their sub-types [3]. Some of the key dysregulated miRNAs
have the potential value to be molecular bio-markers, which can
improve diagnosis, prognosis, and monitoring of treatment
response for human cancers [4–6]. Some miRNAs may function
as oncogenes or tumor suppressors [7–8].
Primary miRNA transcripts are cleaved by Ribonuclease
(RNase) III Drosha in the cell nucleus into 70-nucleotide to 80-
nucleotide precursor miRNA (pre-miRNA) hairpins and trans-
ported to the cytoplasm. Then, pre-miRNAs are processed by
RNase III Dicer into miRNA: miRNA duplexes. One strand of
these duplexes is generally degraded, whereas the other is used as
mature miRNA. Mature miRNAs can recognize and bind into the
39-untranslated region (UTR) of the target mRNAs and interfere
with their translation [9]. It was hypothesized that single
nucleotide polymorphisms (SNPs) within the miRNA sequence
or miRNA target could either weaken or reinforce the binding
between miRNA and target [10].
In the human genome, miR-146a is located at chromosome
5q33. Many recent studies have suggested that miR-146a
expression is deregulated in many solid tumors [11–14]. It became
evident that miR-146a may act as a tumor suppressor. So far, the
possible mechanism through which a miR-146a downmodulation
may contribute to tumor development remains unclear. However,
it seems related to the capacity of this miRNA to target some
mRNAs [15]. A G.C polymorphism has been identified in the
miR-146a gene, and the reference number of this SNP in the
database of the National Center for Biotechnology information
(NCBI) is rs2910164 [16].This polymorphism exists in the stem
region opposite to the mature miR-146a sequence, which leads to
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miR-146a precursor [16].A recent study provided evidence that
the existence of a common G/C polymorphism within the pre-
miR-146a sequence reduced production of miR-146a [17]. This
may lead to a reduced downmodulation of the corresponding
target genes. Several studies have reported that this polymorphism
could contribute to tumorigenesis of many cancers, especially
those belonging to the gastrointestinal (GI) tract, such as gastric
cancer and hepatocellular carcinoma [18–19].
The GI cancers share a number of characteristics that suggest
common etiological pathways or mechanisms. Thus, the identifi-
cation of possible risk factors and carcinogenetic mechanisms is
essential for the prevention of these cancers. Accumulating
evidence has uncovered the important role of inflammatory
network in the promotion of GI cancer development [20]. Regular
use of non-steroidal anti-inflammatory drugs (NSAIDs) could
lower the mortality rate from cancers in the gastrointestinal tract
[21]. Environmental, dietary and endogenous risk factors are
thought to exert important effects on individual predisposition
[10]. From 2008 to 2012, researchers have consecutively reported
associations between miR-146a rs2910164 polymorphism and risk
of GI cancers, but with mixed or even conflicting results [22–33].
Accordingly, we aimed to conduct a meta-analysis to shed more
light on the role of miR-146a rs2910164 polymorphism in
susceptibility to GI cancers.
Materials and Methods
Identification of Eligible Studies
We performed a systematic search using Pubmed, Excerpta
Medica Database (Embase) and Chinese Biomedical Literature
Database (CBM) with the last search updated on February 24,
2012. The following search terms were used: ‘‘microRNA OR mir
OR miRNA’’, ‘‘cancer OR carcinoma OR adenocarcinoma OR
neoplasm OR tumour OR tumor’’, ‘‘gene OR polymorphism OR
allele OR variation’’, and ‘‘146a OR rs2910164’’. Searching was
done without restriction on language or publication years. We
evaluated all associated publications to retrieve the most eligible
literature. Their reference lists were searched manually to identify
additional eligible studies.
Inclusion and Exclusion Criteria
The following inclusion criteria were used in selecting literature
for further meta-analysis: (1) evaluation of miR-146a rs2910164
polymorphism and GI cancers; (2) independent case-control
studies for human; (3) describing useful genotype frequencies; (4)
only full-text manuscripts were included. Exclusion criteria
included: (1) duplication of the previous publications; (2) abstract,
comment, review and editorial; (3) family-based studies of
pedigrees with several affected cases per family. When a study
reported the results on different ethnicities, we treated them as
separate studies. When there were multiple publications from the
same population, only the largest study was included.
Data Extraction
Two investigators independently extracted the data according
to the inclusion criteria listed above. Discrepancies were adjudi-
cated by a third investigator until consensus was achieved on every
item. The following information was extracted from each eligible
study using a standardized data collection protocol (the PRISMA
checklist, Table S1): the first author’s name, year of publication,
source of publication, ethnicity, cancer types, definition and
numbers of cases and controls, and allele as well as genotype
frequencies for cases and controls. If original genotype frequency
data was unavailable in relevant articles, a request for additional
data was sent to the corresponding author.
Quality Score Assessment
The quality of the studies was independently assessed by two
investigators according to a set of predetermined criteria which
was extracted and modified from previous studies [34–35]
(Table 1). These scores were based on traditional epidemiological
considerations, as well as cancer genetic issues. Any disagreement
was resolved by discussion between the two investigators. Scores
ranged from the lowest zero to the highest 18. Articles scoring ,12
were classified as ‘‘low quality’’, and those $12 as ‘‘high quality’’.
Meta-analysis Methods
We used the PRISMA checklist as protocol of the meta-analysis
and followed the guideline (Table S1) [36]. We first assessed
Hardy-Weinberg equilibrium for each study using Chi-square test
in control groups. The odds ratio (OR) and its 95% confidence
interval (95%CI) were used to assess the strength of the association
between miR-146a rs2910164 polymorphism and risk of GI
cancers based on genotype frequencies in cases and controls. The
pooled ORs were performed for allelic comparison (G versus C),
dominant model (GG + GC versus CC), recessive model (GG
versus GC+CC), homozygote comparison (GG versus CC) and
heterozygote comparison (GC versus CC), respectively. The
significance of the pooled OR was determined by the Z-test.
Stratified analyses were performed by ethnicity, cancer types and
quality of studies. A Chi-square test based Q-statistic was
Table 1. Scale for quality assessment.
Criterion Score
Source of cases
Selected from population or cancer registry 3
Selected from hospital 2
Selected from pathology archives, but without description 1
Not described 0
Source of controls
Population-based 3
Blood donors or volunteers 2
Hospital-based (cancer-free patients) 1
Not described 0
Case-control match
Matched by age and gender 3
Not matched by age and gender 0
Specimens used for determining genotypes
White blood cells or normal tissues 3
Tumor tissues or exfoliated cells of tissue 0
Hardy-Weinberg equilibrium in controls
Hardy-Weinberg equilibrium 3
Hardy-Weinberg disequilibrium 0
Total sample size
.1000 3
.500 and ,1000 2
.200 and ,500 1
,200 0
doi:10.1371/journal.pone.0039623.t001
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heterogeneity was not significant, the fixed effect model (using the
Mantel-Haenszel method) was used to estimate the summary OR
and 95% CI; otherwise, the random effect model (using the
DerSimonian and Laird method) was used [38–39]. We also
measured the effect of heterogeneity by another measure,
I
2=100%6(Q-df)/Q [40].
Evaluation of Publication Bias
Potential publication bias was estimated using Egger’s linear
regression test (P,0.05 was considered significant) by visual
inspection of the funnel plot [41]. Analyses were performed using
the software Review Manager 4.2 (Cochrane Collaboration,
http://www.cc-ims.net/RevMan/relnotes.htm/) and Stata ver-
sion 10 (StataCorp LP, College Station, Texas, USA). The pooled
ORs were performed for allelic comparison, dominant model,
recessive model, homozygote comparison and heterozygote
comparison, respectively. Thus, the Bonferroni method was used
to adjust the significance alpha level to correct for the problem of
multiple comparisons. Specifically, the usual significance level
(a=0.05) was divided by 5 to account for five comparisons. Thus,
a P value less than 0.01 was considered statistically significant in
the study, and all the P values were two sided.
Results
Characteristics of Eligible Studies (Table 2)
Main characteristics of the included publications investigating
the association of miR-146a rs2910164 polymorphism with GI
cancers are presented in Table 2. There were 308 articles relevant
to the searching words (Pubmed:98; Embase:199; CBM:11). The
flow chart in Figure 1 summarizes this literature review process. In
the current study, a total of 12 eligible studies (4,817 cases and
5,389 controls) met the inclusion criteria [22–33].
Among the 12 publications, five studies focused on liver cancer
[22,24–26,32], three studies on gastric cancer [27,28,30], two
studies on esophageal cancer [29,33], one study on colorectal
cancer [23] and one study on gallbladder cancer [31], respectively.
Of all studies, ten studies were conducted in Asian populations
[22–24,26–32], and two in Caucasian populations [25,33]. The
results of Hardy-Weinberg equilibrium test for the distribution of
the genotype in control population are shown in Table 2. The
genotype frequency distributions of controls in 10 of 12 studies
were in agreement with HWE. We could not perform the Hardy-
Weinberg equilibrium test for one study, because only the data of
allele frequency was available [33]. Thus, for quality assessment,
this study was considered as Hardy-Weinberg disequilibrium.
Quality scores for the individual studies ranged from 9 to 17, with
83% (10 of 12) of the studies being classified as high quality ($12).
Association between miR-146a rs2910164 Polymorphism
and GI Cancers
The summary of the meta-analysis for miR-196a2 rs11614913
polymorphism and GI cancers is shown in Table 3. We first
analyzed the association in the overall population. Then in order
to obtain the exact consequence of the relationship between miR-
146a rs2910164 polymorphism and GI cancers susceptibility,
stratified analyses by ethnicity, cancer types and quality of studies
were performed. When the Q-test of heterogeneity was not
significant, we conducted analyses using the fixed effect models.
The random effect models were conducted when we detected
significant between-study heterogeneity.
Overall, when all types of GI cancers were considered together
in the meta-analysis, there was no evidence of association between
miR-146a rs2910164 polymorphism and the risk of GI cancers in
any genetic model (G versus C: OR=1.07, 95%CI 0.9821.16,
P=0.14; GG+GC versus CC: OR=1.14, 95%CI 1.0021.31,
P=0.05; GG versus GC+CC: OR=1.06, 95%CI 0.9121.23,
P=0.47; GG versus CC: OR=1.17, 95%CI 0.9521.44, P=0.13;
GC versus CC: OR=1.14, 95%CI 1.0021.31, P=0.05).
Next, we performed subgroup analyses according to ethnicity of
the studies. In Asians, no significant association between miR-146a
rs2910164 polymorphism and the risk of GI cancers was found for
all genetic model (G versus C: OR=1.09, 95%CI 0.9921.19,
P=0.09; GG+GC versus CC: OR=1.15, 95%CI 0.9921.32,
P=0.06; GG versus GC+CC: OR=1.08, 95%CI 0.9121.27,
P=0.37; GG versus CC: OR=1.18, 95%CI 0.9521.47, P=0.14;
GC versus CC: OR=1.14, 95%CI 0.9921.31, P=0.07). In
Caucasians, there was no evidence of association between the
variant genotypes of miR-146a rs2910164 polymorphism and the
Table 2. Characteristics of studies included in the meta-analysis.*
ID Study Year Ethnic group Cancer type Sample size P for HWE Quality score
Case Control
1 Xiang et al. [22] 2012 Asian Liver cancer 100 100 0.506 10
2 Min et al. [23] 2011 Asian Colorectal cancer 446 502 0.443 14
3 Zhou et al. [24] 2011 Asian Liver cancer 186 483 0.056 14
4 Akkız et al. [25] 2011 Caucasian Liver cancer 222 222 0.384 13
5 Zhang et al. [26] 2011 Asian Liver cancer 963 852 0.149 17
6 Okubo et al. [27] 2010 Asian Gastric cancer 552 697 ,0.0001 9
7 Hishida et al. [28] 2010 Asian Gastric cancer 583 699 0.337 15
8 Guo et al. [29] 2010 Asian Esophageal cancer 444 468 0.120 14
9 Zeng et al. [30] 2010 Asian Gastric cancer 304 304 0.122 14
10 Srivastava et al. [31] 2010 Asian Gallbladder cancer 230 230 0.080 15
11 Xu et al. [32] 2008 Asian Liver cancer 479 504 0.119 14
12 Ye et al. [33] 2008 Caucasian Esophageal cancer 346 346 NA 12
*HWE, Hardy-Weinberg equilibrium; NA, not available.
doi:10.1371/journal.pone.0039623.t002
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OR=0.94, 95%CI 0.7721.14, P=0.51).
Moreover, we investigated the effect of the miR-146a rs2910164
polymorphism on the susceptibility to subtypes of GI cancers. No
evidence of association was observed in any genetic model
between miR-146a rs2910164 polymorphism and risk of liver
cancer (G versus C: OR=1.07, 95%CI 0.9821.18, P=0.13;
GG+GC versus CC: OR=1.11, 95%CI 0.9621.27, P=0.15; GG
versus GC+CC: OR=1.08, 95%CI 0.9221.27, P=0.34; GG
versus CC: OR=1.18, 95%CI 0.9721.43, P=0.10; GC versus
CC: OR=1.09, 95%CI 0.9421.26, P=0.27), gastric cancer (G
versus C: OR=1.05, 95%CI 0.8921.24, P=0.54; GG+GC
versus CC: OR=1.15, 95%CI 0.8821.51, P=0.31; GG versus
GC+CC: OR=0.93, 95%CI 0.7721.13, P=0.48; GG versus CC:
OR=1.04, 95%CI 0.7421.47, P=0.81; GC versus CC:
OR=1.20, 95%CI 0.8821.64, P=0.26) and esophageal cancer
(G versus C: OR=1.15, 95%CI 0.8021.66, P=0.46).
We also performed subgroup analysis according to quality of
studies. In the subgroup of high quality studies, no significant
association between miR-146a rs2910164 polymorphism and risk
of GI cancers was observed (G versus C: OR=1.07, 95%CI
0.9721.18, P=0.19; GG+GC versus CC: OR=1.14, 95%CI
0.9621.35, P=0.13; GG versus GC+CC: OR=1.09, 95%CI
0.9421.27, P=0.25; GG versus CC: OR=1.22, 95%CI
0.9721.53, P=0.09; GC versus CC: OR=1.12, 95%CI
0.9521.31, P=0.18). In the subgroup of low quality studies,
there was also no evidence of association between miR-146a
rs2910164 polymorphism and the risk of GI cancers in any genetic
model (G versus C: OR=1.02, 95%CI 0.8821.19, P=0.79;
GG+GC versus CC: OR=1.16, 95%CI 0.9421.44, P=0.61; GG
versus GC+CC: OR=0.94, 95%CI 0.5021.76, P=0.85; GG
versus CC: OR=0.91, 95%CI 0.6721.23, P=0.54; GC versus
CC: OR=1.29, 95%CI 1.0221.61, P=0.03).
Evaluation of Publication Bias (Table 4)
The results of Egger’s linear regression test are shown in Table 4.
The shape of the funnel plots did not reveal any evidence of
obvious asymmetry for all genetic models in the overall meta-
analysis. Egger’s test was used to provide statistical evidence of
funnel plot symmetry. The intercept a provides a measure of
asymmetry, and the larger its deviation from zero the more
pronounced the asymmetry. The results still did not present any
obvious evidence of publication bias for any of the genetic models.
Egger’s test only detected evidence of publication bias in the
subgroup analysis of gastric cancer for allelic contrast (P=0.004).
However, Egger’s test was not applied in some comparisons due to
the small number of studies.
Discussion
In the present meta-analysis with 4,817 cases and 5,389
controls, there was no evidence of association between miR-
146a rs2910164 polymorphism and the risk of GI cancers. Similar
results were found in the subgroup analyses by ethnicity, cancer
types, and quality of studies. The current study is the largest meta-
analysis of the association between miR-146a rs2910164 poly-
morphism and the risk of GI cancers.
Figure 1. The flow chart of the included studies in the meta-analysis.
doi:10.1371/journal.pone.0039623.g001
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Comparisons Sample size
No. of
Studies Test of association Test of heterogeneity
Case Control OR (95%CI) Z P-value Model x
2 P-value I
2(%)
Overall G vs C 9634 10778 12 1.07(0.98–1.16) 1.46 0.14 R 21.64 0.03 49.2
GG+GC vs CC 4471 5043 11 1.14(1.00–1.31) 1.94 0.05 R 18.23 0.05 45.1
GG vs GC+CC 4471 5043 11 1.06(0.91–1.23) 0.72 0.47 R 20.47 0.03 51.2
GG vs CC 2394 2767 11 1.17 (0.95–1.44) 1.50 0.13 R 21.91 0.02 54.4
GC vs CC 3396 3915 11 1.14(1.00–1.31) 1.92 0.05 R 16.25 0.09 38.5
Asian G vs C 8498 9642 10 1.09(0.99–1.19) 1.70 0.09 R 19.87 0.02 54.7
GG+GC vs CC 4249 4821 10 1.15(0.99–1.32) 1.88 0.06 R 18.22 0.03 50.6
GG vs GC+CC 4249 4821 10 1.08(0.91–1.27) 0.89 0.37 R 19.50 0.02 53.9
GG vs CC 2247 2612 10 1.18(0.95–1.47) 1.48 0.14 R 21.88 0.009 58.9
GC vs CC 3311 3837 10 1.14(0.99–1.31) 1.82 0.07 R 16.22 0.06 44.5
Caucasian G vs C 1136 1136 2 0.94(0.77–1.14) 0.65 0.51 F 0.02 0.90 0.0
Liver cancer G vs C 3824 4298 5 1.07(0.98–1.18) 1.50 0.13 F 5.83 0.21 31.4
GG+GC vs CC 1912 2149 5 1.11(0.96–1.27) 1.44 0.15 F 3.69 0.45 0.0
GG vs GC+CC 1912 2149 5 1.08(0.92–1.27) 0.95 0.34 F 7.33 0.12 45.4
GG vs CC 1015 1147 5 1.18 (0.97–1.43) 1.65 0.10 F 5.76 0.22 30.6
GC vs CC 1479 1704 5 1.09(0.94–1.26) 1.10 0.27 F 3.28 0.51 0.0
Gastric cancer G vs C 2878 3400 3 1.05(0.89–1.24) 0.62 0.54 R 4.99 0.08 59.9
GG+GC vs CC 1439 1700 3 1.15(0.88–1.51) 1.01 0.31 R 6.72 0.03 70.3
GG vs GC+CC 1439 1700 3 0.93(0.77–1.13) 0.71 0.48 F 4.41 0.11 54.7
GG vs CC 772 972 3 1.04(0.74–1.47) 0.25 0.81 R 4.98 0.08 59.9
GC vs CC 1222 1430 3 1.20(0.88–1.64) 1.13 0.26 R 7.77 0.02 74.3
Esophageal cancer G vs C 1580 1628 2 1.15(0.80–1.66) 0.74 0.46 R 5.26 0.02 81.0
High quality G vs C 8330 9184 10 1.07(0.97–1.18) 1.31 0.19 R 20.13 0.02 55.3
GG+GC vs CC 3819 4246 9 1.14(0.96–1.35) 1.52 0.13 R 18.03 0.02 55.6
GG vs GC+CC 3819 4246 9 1.09(0.94–1.27) 1.15 0.25 R 13.95 0.08 42.6
GG vs CC 2030 2270 9 1.22(0.97–1.53) 1.67 0.09 R 17.51 0.03 54.3
GC vs CC 2844 3260 9 1.12(0.95–1.31) 1.35 0.18 R 14.70 0.07 45.6
Low quality G vs C 1304 1594 2 1.02(0.88–1.19) 0.26 0.79 F 1.18 0.28 15.1
GG+GC vs CC 652 797 2 1.16(0.94–1.44) 1.41 0. 61 F 0.09 0.77 0.0
GG vs GC+CC 652 797 2 0.94(0.50–1.76) 0. 19 0. 85 R 3.10 0.08 67.7
GG vs CC 364 497 2 0.91(0.67–1.23) 0.61 0.54 F 2.07 0.15 51.7
GC vs CC 552 655 2 1.29(1.02–1.61) 2.16 0.03 F 0.12 0.73 0.0
*OR, odds ratio; vs, versus; R, random effect model; F, fixed effect model.
doi:10.1371/journal.pone.0039623.t003
Table 4. Egger’s linear regression test to measure the funnel plot asymmetric.*
Groups Y axis intercept: a (95%CI)
Gv sC G G +GC vs CC GG vs GC + CC GG vs CC GC vs CC
Overall 0.02 (23.3323.37) 0.29(22.0222.60) 0.80(23.5725.17) 0.75(22.2423.74) 0.02(22.1922.23)
Asian 0.85(23.3425.05) 0.40(22.4723.28) 1.07(23.5925.72) 1.06(22.5824.70) 20.06(22.81–2.70)
Liver cancer 0.24(25.2025.67) 20.01(23.5623.55) 2.18(24.0328.38) 0.90(23.8125.60) 20.20 (23.5323.13)
Gastric cancer 8.70(7.98–9.43) 7.20(253.24–67.63) 7.63(288.45–103.70) 9.47(218.33–37.26) 6.26(280.96–93.49)
High quality 20.81(25.23–3.61) 0.25(22.78–3.26) 20.09(25.72–5.54) 0.25(23.33–3.84) 0.16(22.60–2.91)
*vs, versus.
doi:10.1371/journal.pone.0039623.t004
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the association between miR-146a rs2910164 polymorphism and
overall cancer risk. Xu et al. [42] and Qiu et al. [43] both
identified that miR-146a rs2910164 polymorphism was not
associated with overall cancer risk. In another meta-analysis,
overall increased cancer risk was only found in dominant model
(P=0.02) [44]. Nevertheless, the authors did not adjust the
significance alpha level. If multiple comparisons were corrected,
a negative result would be obtained. In consistent with these
reports, we did not find any association between miR-146a
rs2910164 polymorphism and the risk of GI cancers in overall
analysis. When stratified by cancer types, Xu et al. [42] found that
the C allele of miR-146a rs2910164 polymorphism might be
associated with protection from digestive cancer in subgroup
analysis. But the subgroup analysis only included three studies
[29,31,32]. Contrary to the result, our meta-analysis provided
more sufficient evidence that miR-146a rs2910164 was not
a functional polymorphism on GI cancers susceptibility based on
larger sample sizes and increased statistical power. Similarly, in
subgroup analysis, we consistently showed no association between
this SNP and GI cancers.
The current meta-analysis is based on a single polymorphism
strategy to explore the association between miR-146a gene
polymorphism and GI cancers. Duan and colleagues have
identified 323 SNPs in 227 human known miRNAs [45]. Though
a single SNP has limited effect on the risk of GI cancers,
interactions of multiple SNPs in miRNA-related genes might
augment the effect. Development of GI cancers is a multistage
process, and a single polymorphism might have a limited impact
on GI cancers susceptibility [10]. More comprehensive haplotype-
based or multiple polymorphisms-based strategies rather than
a single polymorphism-based strategy are warranted, which may
provide more precise information on genetic contribution of miR-
146a gene polymorphism to GI cancers etiology. In addition to
genetic predisposition, environmental exposure, such as smoking,
alcohol consumption, and diet, is also thought to play a crucial role
in the etiology of GI cancers [46]. Gene-environment interactions
should be considered in further studies if individual data of
environmental exposure are available.
Certain potential limitations exist in our meta-analysis. Firstly,
the controls for one study included in this meta-analysis were not
in Hardy-Weinberg equilibrium. To some extent, the results of
genetic association studies might be distorted. Secondly, publica-
tion bias was detected in the subgroup analysis of gastric cancer for
allelic contrast. This may also distort the meta-analysis. Thirdly, as
with most meta-analyses, results should be interpreted with
caution because of obvious between-study heterogeneity in some
comparisons. Fourthly, if individual data were available, we could
perform a more precise analysis with an adjustment estimate.
Finally, colorectal cancer is the commonest cancer of the
alimentary tract. Lacking sufficient eligible studies on colorectal
cancer limited our further stratified analyses.
In conclusion, results from meta-analysis of published data show
that miR-146a rs2910164 polymorphism is not associated with GI
cancers susceptibility. It is necessary to conduct more well-
designed studies based on larger sample sizes and homogeneous
cancer patients.
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